Trends over time in the incidence and use of hormonal therapy in endometrial cancer: a population-based study in the Netherlands

Willem Jan van Weelden*, Reini Bretveld, Andrea Romano, Stephan van Erp, Sam Engels, Roy Lalisang, Johanna Pijnenborg, Maaike van der Aa

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction According to current guidelines, hormonal therapy may be applied in endometrioid type endometrial cancer as an alternative to surgery for fertility preservation and in medically unfit patients. Since it is unknown how often hormonal therapy is applied, the objective of this study was to investigate trends over time in hormonal therapy use in the background of the overall incidence of endometrial cancer. Methods All patients with endometrial cancer (n=48 222) registered in the Netherlands Cancer Registry in the period 1989-2018 were included. European age-standardized incidence rates with corresponding estimated annual percentage change were calculated to describe trends in the incidence of endometrial cancer. The use of hormonal therapy was analyzed in the three periods 1989-1998, 1999-2008, and 2009-2018 for the following sub-groups: primary and adjuvant therapy, International Federation of Gynecology and Oncology (FIGO) stage I-II and III-IV, and by age group. Results The European age-standardized incidence rate of endometrioid endometrial cancer peaked in 2004 with a significant increase from 1989 to 2004 (annual percentage change 0.55; 95% CI 0.10 to 0.99, p=0.020) and a subsequent decrease from 2005 to 2018 (annual percentage change -1.79; 95% CI -2.28 to -1.31, p= 75 years. Adjuvant hormonal treatment was mostly used in advanced stage endometrial cancer. Conclusions The use of primary hormonal therapy in endometrioid type endometrial cancer increased over time in patients aged

Original languageEnglish
Pages (from-to)1014-1020
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume31
Issue number7
DOIs
Publication statusPublished - Jul 2021

Keywords

  • endometrial neoplasms
  • obesity
  • morbid
  • COMPLEX ATYPICAL HYPERPLASIA
  • IMPROVED SURVIVAL
  • CARCINOMA
  • STAGE
  • MANAGEMENT
  • RADIOTHERAPY
  • RISK
  • ADENOCARCINOMA
  • CHEMOTHERAPY
  • PROGESTIN

Cite this